1. Home
  2. COLL vs OBK Comparison

COLL vs OBK Comparison

Compare COLL & OBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • OBK
  • Stock Information
  • Founded
  • COLL 2002
  • OBK 1912
  • Country
  • COLL United States
  • OBK United States
  • Employees
  • COLL N/A
  • OBK N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • OBK Major Banks
  • Sector
  • COLL Health Care
  • OBK Finance
  • Exchange
  • COLL Nasdaq
  • OBK Nasdaq
  • Market Cap
  • COLL 864.7M
  • OBK 944.2M
  • IPO Year
  • COLL 2015
  • OBK 2018
  • Fundamental
  • Price
  • COLL $30.23
  • OBK $34.19
  • Analyst Decision
  • COLL Strong Buy
  • OBK Buy
  • Analyst Count
  • COLL 5
  • OBK 5
  • Target Price
  • COLL $43.80
  • OBK $42.20
  • AVG Volume (30 Days)
  • COLL 321.1K
  • OBK 138.1K
  • Earning Date
  • COLL 05-08-2025
  • OBK 04-23-2025
  • Dividend Yield
  • COLL N/A
  • OBK 1.76%
  • EPS Growth
  • COLL N/A
  • OBK N/A
  • EPS
  • COLL 1.25
  • OBK 2.43
  • Revenue
  • COLL $664,283,000.00
  • OBK $351,348,000.00
  • Revenue This Year
  • COLL $20.00
  • OBK $13.16
  • Revenue Next Year
  • COLL $3.74
  • OBK $6.03
  • P/E Ratio
  • COLL $24.13
  • OBK $14.03
  • Revenue Growth
  • COLL 17.17
  • OBK 2.92
  • 52 Week Low
  • COLL $23.23
  • OBK $28.80
  • 52 Week High
  • COLL $42.29
  • OBK $41.17
  • Technical
  • Relative Strength Index (RSI)
  • COLL 64.41
  • OBK 62.54
  • Support Level
  • COLL $28.81
  • OBK $32.16
  • Resistance Level
  • COLL $30.17
  • OBK $34.86
  • Average True Range (ATR)
  • COLL 1.02
  • OBK 0.66
  • MACD
  • COLL 0.37
  • OBK 0.34
  • Stochastic Oscillator
  • COLL 93.13
  • OBK 81.34

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

Share on Social Networks: